Jasper Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Jasper Therapeutics R&D Spending Growth & History (JSPR)
Jasper Therapeutics's r&d spending was $63.1M for fiscal 2025.
View full Jasper Therapeutics company overviewJasper Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $63.1M | $7.3M | +13.05% |
| 2024 | 2024-12-31 | $55.8M | $4.0M | +7.79% |
| 2023 | 2023-12-31 | $51.8M | $50.9M | +6050.24% |
| 2022 | 2022-12-31 | $842,000 | $703,000 | +505.76% |
| 2021 | 2021-12-31 | $139,000 | −$38,000 | −21.47% |
| 2020 | 2020-12-31 | $177,000 | — | — |
Jasper Therapeutics quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.1M | −$16.1M | −75.77% |
| Q1 2026 | 2026-03-31 | $5.8M | −$10.3M | −64.02% |
| Q4 2025 | 2025-12-31 | $11.4M | −$8.4M | −42.55% |
| Q3 2025 | 2025-09-30 | $14.4M | −$64,000 | −0.44% |
| Q2 2025 | 2025-06-30 | $21.2M | $9.9M | +87.64% |
| Q1 2025 | 2025-03-31 | $16.2M | $5.9M | +56.89% |
| Q4 2024 | 2024-12-31 | $19.8M | −$2.9M | −12.96% |
| Q3 2024 | 2024-09-30 | $14.5M | −$393,000 | −2.65% |
| Q2 2024 | 2024-06-30 | $11.3M | −$2.0M | −15.05% |
| Q1 2024 | 2024-03-31 | $10.3M | $9.4M | +1013.30% |
| Q4 2023 | 2023-12-31 | $22.7M | $21.9M | +2597.74% |
| Q3 2023 | 2023-09-30 | $14.8M | $5.8M | +64.58% |
| Q2 2023 | 2023-06-30 | $13.3M | $13.2M | +23644.64% |
| Q1 2023 | 2023-03-31 | $925,000 | $356,000 | +62.57% |
| Q4 2022 | 2022-12-31 | $842,000 | — | — |
| Q3 2022 | 2022-09-30 | $9.0M | $1.8M | +25.51% |
| Q2 2022 | 2022-06-30 | $56,000 | −$5.1M | −98.91% |
| Q1 2022 | 2022-03-31 | $569,000 | −$3.9M | −87.13% |
| Q3 2021 · Sep 30 | 2021-09-30 | $7.2M | $2.7M | +59.03% |
| Q2 2021 | 2021-06-30 | $5.2M | — | — |
| Q1 2021 | 2021-03-31 | $4.4M | — | — |
| Q3 2020 | 2020-09-30 | $4.5M | — | — |
Jasper Therapeutics r&d spending trends
Over the last five fiscal years, Jasper Therapeutics's r&d spending increased from $177,000 to $63.1M, a change of $62.9M. The latest reported quarter, Q2 2026, shows $5.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Jasper Therapeutics source filings ↗